The International Immunoglobulin Conference
For three decades, CSL Behring has sponsored a series of high-level scientific meetings in Interlaken, Switzerland.
First held in 1981, the International Immunoglobulin Conference (previously Symposium) focuses on scientific and clinical research in the field of polyvalent immunoglobulins.
Research presented at the International Immunoglobulin Conference is consistently at the forefront of immunoglobulin research and clinical practice.
Since its inception, the Conference has won the respect and support of top international scientists and clinicians from many different fields of research.
More than 200 scientists and clinicians attended the 7th International Immunoglobulin Conference, which was held in Interlaken on
April 4-5, 2014. Attendees discussed findings from a broad range of immunoglobulin research with a focus on Immunology, Neurology
and Transplantation. Proceedings from the 7th IIC will be published at the end of 2014.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We
research, develop, manufacture and market biotherapies that are used to treat serious
and rare conditions. Users of our therapies rely on them for their quality of life
and, in many cases, for life itself.
Our commitment to saving lives and improving the quality of life for people with
serious and rare conditions is evident in everything we do. Whether we are manufacturing
and marketing safe and effective products or researching and developing innovative
biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
In 1981, CSL Behring’s predecessor company released Sandoglobulin®,the first non-modified
immunoglobulin concentrate marketed worldwide for intravenous infusion. Today, CSL
Behring continues to demonstrate its commitment to immunoglobulin research by sponsoring
the International Immunoglobulin Conference and the Interlaken Leadership Awards.